SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

By M. Hoffmann, Hannah Kleine-Weber, S. Schroeder, Nadine Krüger, T. Herrler, Sandra Erichsen, T. Schiergens, G. Herrler, N. Wu, Andreas Nitsche and 3 more. 2020

18,267 citations recorded by the source corpus.

Summary The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency. Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets. Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option. Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry. Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention.

Subfields: Infectious Diseases

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

  1. D. Veesler
  2. Jesse D. Bloom
  3. Fang Li
  4. F. Krammer
  5. M. A. Tortorici
  6. J. Shang
  7. Yushun Wan
  8. Ralph S. Baric

Citations in the corpus